ClinicalTrials.gg

Program

xaluritamig

Also written as “Xaluritamig” and “AMG 509”.

Its studies are mostly in Prostatic Neoplasms · Sarcoma, Ewing, led by Amgen.

Furthest: phase 3, since Nov 14, 20247 company-led studies, 7 open or runningNext primary completion: Feb 17, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen77 open or runningphase 3since Nov 14, 2024Dec 16, 2019Feb 17, 2027phase 1 · NCT06613100

Also a collaborator on its studies: BeOne Medicines.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2019First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04221542 · 505 planned · United States, Australia, China and more
  2. Aug 13, 2024Phase 1 study in Prostatic NeoplasmsNCT06555796 · 50 enrolled · United States, Australia
  3. Sep 23, 2024Phase 1 study in Prostatic NeoplasmsNCT06613100 · 40 planned · United States, Germany
  4. Nov 14, 2024Phase 3 study in NeoplasmsNCT06691984 · 707 enrolled · United States, Australia, Austria and more
  5. Sep 18, 2025Phase 3 study in Prostatic NeoplasmsNCT07213674 · 750 planned · United States, Australia, Austria and more
  6. Dec 9, 2025Phase 1 study in Sarcoma, EwingNCT07297979 · 50 planned · United States, Australia
  7. Mar 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07493512 · 40 planned · United States, Australia
  8. Nov 12, 2026Primary completion moved from 2030-03-22 to 2030-07-28Date moved laterphase 1 · +4 months · NCT04221542

Ahead

  1. Feb 17, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06613100
  2. Mar 13, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06555796
  3. Jan 2, 2029Primary completion: phase 3 study in NeoplasmsNCT06691984
  4. Jan 7, 2030Primary completion: phase 3 study in Prostatic NeoplasmsNCT07213674

TargetBeta

CD3E →STEAP1 →read by rule
“A humanized immunoglobulin G1 (IgG1) bispecific antibody directed against both the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HLX3902Fosun Pharmaphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07493512Prostatic Neoplasms · United States, Australia1RecruitingJul 30, 203040
NCT07297979Sarcoma, Ewing · United States, Australia1RecruitingMay 26, 203050
NCT07213674Prostatic Neoplasms · United States, Australia, Austria and more3RecruitingJan 7, 2030750
NCT06691984Neoplasms · United States, Australia, Austria and more3Active, not recruitingJan 2, 2029707
NCT06613100Prostatic Neoplasms · United States, Germany1RecruitingFeb 17, 202740
NCT06555796Prostatic Neoplasms · United States, Australia1Active, not recruitingMar 13, 202750
NCT04221542Prostatic Neoplasms · United States, Australia, China and more1RecruitingJul 28, 2030505

How it is read

Names in the registry

  • “Xaluritamig”, 6 entries
  • “AMG 509”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.